Patients with systemic lupus erythematosus (SLE) who adhered to antimalarials (AM) therapy lowered their risk of death by up to 71% compared to patients who did not adhere to AM therapy and 83% compared to those who discontinued AM, according to a study.
A total of 3062 individuals with SLE who were treated with AM were included and followed from their first day of therapy over a mean follow-up of 6.4 years. During this study period, 7.9% (n = 242) of patients died.
The adjusted hazard ratios (aHRs) from Cox’s model for patients who were AM adherent were 0.20 (95% CI:0.13‐0.29) and for patients who were non‐adherent aHRs were 0.62 (95% CI:0.42‐0.91, compared to discontinuers.
The authors concluded that there was a significant trend in mortality risk over the adherence levels was found (P < 0.001).
Hoque MR, Avina-Zubieta JA, De Vera MA, et al. Impact of antimalarial adherence on mortality among patients with newly diagnosed systemic lupus erythematosus: A population‐based cohort study. Arthritis Care Res. 2021; https://doi.org/10.1002/acr.24550.